FEcal tranSplantation in HidradeniTIs suppuratiVA : a piLot Study
Key facts
- Where
- Bordeaux, Clermont-Ferrand, Lyon, Marseille, Montpellier, and Rodez, FranceSee the 7 sites
- Phase
- Phase 1
Where in France
- CHU Bordeaux Hopital Saint AndreBordeaux, FranceContact: Marie BEYLOT-BARRY (principal investigator)No longer taking part
- CHU Clermont Ferrand, PIC/CICClermont-Ferrand, FranceContact: Gisèle PICKERING (principal investigator)No longer taking part
- CHU Clermont-FerrandClermont-Ferrand, FranceContact: lise LaclautreNo longer taking part
- Chu LyonLyon, FranceContact: Axel VILLANI (principal investigator)No longer taking part
- CHU Marseille - La TimoneMarseille, FranceContact: Marie-Aleth RICHARD (principal investigator)No longer taking part
- CHU MontpellierMontpellier, FranceContact: Céline GIRARD (principal investigator)No longer taking part
- CH RodezRodez, FranceContact: Claire HOTZ (principal investigator)No longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital, Clermont-Ferrand
- Trial code
- NCT07668713
- Record updated
- 25 June 2026
- Original description
The medical and surgical treatment of hidradenitis suppurativa (HS) remains difficult to date. The search for new therapies for HS is a major challenge. The pathophysiology of HS, the similarities with Crohn's disease and the data in the literature suggest a role for the digestive flora in HS. The role of the intestinal microbiota has now been clearly demonstrated in the pathophysiology of chronic inflammatory bowel disease (IBD), and is suspected in many other diseases. Fecal microbiota transplantation (FMT) is the gold-standard treatment for recurrent Clostridioides Difficile infection, and is being investigated in a wide range of conditions. Our hypothesis is that FMT would improve inflammatory lesions of HS by modifying patients' digestive microbiota.Read full original descriptionShow less
The medical and surgical treatment of hidradenitis suppurativa (HS) remains difficult to date. The search for new therapies for HS is a major challenge. The pathophysiology of HS, the similarities with Crohn's disease and the data in the literature suggest a role for the digestive flora in HS. The role of the intestinal microbiota has now been clearly demonstrated in the pathophysiology of chronic inflammatory bowel disease (IBD), and is suspected in many other diseases. Fecal microbiota transplantation (FMT) is the gold-standard treatment for recurrent Clostridioides Difficile infection, and is being investigated in a wide range of conditions. Our hypothesis is that FMT would improve inflammatory lesions of HS by modifying patients' digestive microbiota.
Translated with DeepL.com (free version)
Inclusion: Age ≥ 18 years; Patient with Hurley HS II (moderate severity) or III (very severe); Axillomammary (LC1) or gluteal (LC3) phenotype with at least 4 inflammatory lesions: inflammatory nodule, abscess or active fistula; Having presented at least one relapse to a well-conducted medical treatment as proposed by the 2019 French Dermatology Society evidence center recommendations (broad-spectrum antibiotic therapy for 15 to 21 days followed by prophylactic treatment with doxycycline or cotrimoxazole). A relapse is defined as the occurrence of a new attack within 3 months of the introduction of treatment.
Exclusion: Patient having received biomedication in the 3 months prior to inclusion; Concomitant Clostridioides Difficile infection; Allergy or contraindication to amoxicillin-clavulanic acid; Patient suffering from another inflammatory disease (IBD, inflammatory rheumatism, auto-inflammatory disease); HIV infection and active HBV/HCV hepatitis; Immunocompromised patients; No health insurance; Pregnant or breast-feeding women; Patients already included in a biomedical research study other than an observational study (e.g. registry, cohort); Patients under guardianship/curatorship/legal protection.